ArticleClinical and translational allergy2019
Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study.
Article in Clinical and translational allergy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- CH50 as a Clinically Useful Biomarker of Disease Activity and Antihistamine Resistance in Chronic Spontaneous Urticaria: An Observational Ambispective Single-Center Study.International journal of dermatology · 2026Observational
- Clinical and Immunological Associations of Plasma Platelet-Activating Factor in Chronic Spontaneous Urticaria.Biomedicines · 2026Article
- Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines.The Korean journal of internal medicine · 2026Review
- Basophil FCER1A and PTAFR Gene Expression Profiles Correlate With Disease Severity in Chronic Spontaneous Urticaria.Clinical and translational allergy · 2026Article
- Lands' Cycle at the Crossroads: Phospholipid Remodelling, Oxidative Stress, Cellular Toxicity, and Therapeutic Targeting.ACS pharmacology & translational science · 2025Review
- The Predictive Value of Serum Total IgE for Antihistamine Treatment Outcomes in Chinese Patients with Chronic Spontaneous Urticaria.Acta dermato-venereologica · 2025Article
- Predictors of early treatment response to antihistamines and omalizumab in chronic spontaneous urticaria.Frontiers in allergy · 2025Review
- Role of Platelet-Activating Factor in the Pathogenesis of Chronic Spontaneous Urticaria.International journal of molecular sciences · 2024Review
- Identifying patients at risk of anaphylaxis.The World Allergy Organization journal · 2024Review
- How to handle off-label prescriptions of rupatadine, a second-generation antihistamine and PAF antagonist: a review.Drugs in context · 2024Review
- Disease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticaria.The World Allergy Organization journal · 2023Article
- Serum Levels of Vascular Endothelial Growth Factor, Platelet Activating Factor and Eosinophil-Derived Neurotoxin in Chronic Spontaneous Urticaria-A Pilot Study in Adult Patients.International journal of molecular sciences · 2022Article
- Effects of a 12-week whole-grain or refined wheat intervention on plasma acylcarnitines, bile acids and signaling lipids, and association with liver fat: AFrontiers in nutrition · 2022Article
- Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.Clinical reviews in allergy & immunology · 2021Review
- Total IgE as a Marker for Chronic Spontaneous Urticaria.Allergy, asthma & immunology research · 2021Review
- Highlights and recent developments in allergic diseases in EAACI journals (2019).Clinical and translational allergy · 2020Review
- Coronavirus 2019, Microthromboses, and Platelet Activating Factor.Clinical therapeutics · 2020Article
- Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatelet activating factor (PAF) is an endogenous, active phospholipid released from inflammatory cells, platelets, and endothelial cells, and is involved in the regulation of immune responses. Degradation of PAF by PAF acetylhydrolase (PAF-AH) has been shown to be associated with anaphylaxis, asthma, and peanut allergy. The purpose of this study was to investigate relationships among clinical parameters, including urticaria severity and treatment responsiveness, and PAF and PAF-AH levels in sera from patients with chronic spontaneous urticaria (CSU).
methodsSerum PAF and PAF-AH levels were measured by enzyme-linked immunosorbent assay in 283 CSU patients and 111 age- and sex-matched, healthy normal controls (NCs). Urticaria severity was evaluated by urticaria activity score over 7 days (UAS7). Within 3 months after measuring PAF levels, patients whose urticaria was not controlled by antihistamine treatment were classified as histamine receptor 1 antagonist (H1RA) non-responders.
resultsSerum PAF levels were significantly higher in CSU patients than in NCs (median 4368.9 vs. 3256.4 pg/ml, p = 0.015), while serum PAF-AH levels were significantly lower in CSU patients (105.6 vs. 125.7 ng/ml, p = 0.001). H1RA non-responders had higher levels of PAF in their sera than H1RA responders. A generalized linear model revealed that a higher UAS7 score (odds ratio 1.023, p = 0.024) and a PAF level ≥ 5000 pg/ml (1.409, p < 0.001) were significant predictors of a poor response to H1RA treatment.
conclusionsCompared with NCs, CSU patients, particularly those with H1RA refractoriness, showed significant increases in serum PAF levels and decreases in PAF-AH. Therapies modulating PAF and PAF-AH levels could be effective in patients with CSU refractory to antihistamines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.